GIFT Nifty Opening Update
GIFT Nifty opened today at 23,950.00. It is down -806.50 points (-3.28%) from yesterday’s close of 24,574.00— so the trend is negative.
The Indian stock market benchmark indices, the BSE Sensex and Nifty 50, are expected to open significantly lower on Monday, following a global market sell-off amid rising crude oil prices. The increase in oil prices came in response to the escalating US-Israeli conflict with Iran, leading to worries about reduced supply and possible interruptions to shipments via the Strait of Hormuz. Asian markets experienced a decline, and the US stock market also finished lower last week, as the intensifying conflict in the Middle East negatively impacted investor sentiment. “Indian equity markets are anticipated to commence with caution as ongoing geopolitical tensions in the Middle East maintain high crude oil prices and contribute to a fragile global risk sentiment. Investor confidence continues to be cautious after the significant downturn observed in both global and domestic equity markets last week. While steady inflows from Domestic Institutional Investors (DIIs) are providing a key support base and partially offsetting selling pressure from Foreign Portfolio Investors (FPIs), the broader market mood remains defensive,” stated Ponmudi R.
On Friday, the Indian stock market closed with significant losses due to persistent concerns regarding the US-Iran conflict, increasing crude oil prices, and ongoing foreign capital outflows. The Sensex plunged 1,097.00 points, or 1.37%, to finish at 78,918.90, while the Nifty 50 declined 315.45 points, or 1.27%, to settle at 24,450.45. In light of the ongoing US-Iran conflict, attention will likely be directed towards these stocks on Monday, March 9, 2026 —
Equities to Monitor:
- PB Fintech experienced significant block transactions totaling approximately Rs 695 crore on Friday, with shares being acquired by Goldman Sachs, mutual funds, and foreign institutional investors from a current stakeholder.
- Kwality Walls – In Q3 FY26, the company reported revenue of Rs 222 crore, with its impulse portfolio achieving mid-single-digit volume growth for the quarter.
- Meesho has been issued an assessment order for the Assessment Year 2023–24, accompanied by a demand notice from the Income Tax Department, which has raised a tax demand of Rs 1,499.73 crore, inclusive of applicable interest.
- AU Small Finance Bank – The Reserve Bank of India on Saturday communicated to AU Small Finance Bank that it has amended its previous approval concerning the lender’s shift to a universal bank, allowing promoter shareholding to persist for the time being without the establishment of a Non-Operating Holding Company (NOHC).
- Tata Power has revealed a collaboration with Salesforce aimed at digitally transforming its rapidly expanding rooftop solar, EV charging, and smart home solutions sectors.
- Dr Reddy’s Lab announced that it has received a communication from the US Department of Justice indicating that, following the review of the information, the department has completed its inquiry under the Foreign Corrupt Practices Act (FCPA).
- UltraTech Cement has entered into an Energy Supply Agreement, Share Subscription Agreement, and Shareholders Agreement to obtain a 26.20% equity stake in Sunsure Solarpark Thirty Eight Private Limited, a company engaged in the generation and transmission of renewable energy.
- RITES has obtained updated projections from South Western Railway regarding the railway electrification project for the Mysuru–Hassan–Mangaluru corridor, which encompasses the Hassan–Arsikere segment, to be executed on a cost-plus turnkey arrangement. The updated project expenditure is Rs 729.28 crore.
- Yes Bank’s board has given the green light for Vinay Muralidhar Tonse to take on the role of Managing Director and CEO (Designate), starting March 12, leading up to his official start date on April 5.
- Cipla – A US-based subsidiary of drugmaker Cipla is recalling over 400 cartons of a generic anti-cancer drug due to a manufacturing defect, as reported by the U.S. Food and Drug Administration (USFDA).